hAd5 ACE2 decoy - ImmunityBio
Alternative Names: ACE2 Decoy COVID-19 Therapeutic - ImmunityBio; ACE2 Triple Decoy - ImmunityBio; ACE2(N27Y/H34A/H374N)-IgG1FC fusion protein decoy; ACE2(T27Y/H34A/H374N)-IgG1FC Triple Decoy; SARS-CoV-2 Neutralising ACE2 Decoy - ImmunityBioLatest Information Update: 28 Apr 2025
At a glance
- Originator ImmunityBio
- Class COVID-19 vaccines; Protein vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections